To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Key Inclusion Criteria:

- Subjects with a clinical diagnosis of discoid lupus erythematosus or sub acute lupus
erythematosus for > 16 weeks prior to screening and consistent histological findings
on skin biopsy based on Gilliam classification who are candidates for systemic
therapies (as determined by the Investigator)

- Must, in the opinion of the Investigator, have active skin lesions of sufficient
severity at Screening and Baseline (a Cutaneous Lupus Area and Severity Index
Activity Score of ≥ 10)

- All subjects taking hydroxychloroquine, chloroquine or quinacrine during the study
must have documentation of an ophthalmologic exam performed within 24 weeks of the
Baseline Visit.

- Must meet the following laboratory criteria:

- White blood cell count ≥3000/mm3 (≥ 3.0 x 109/L) and < 14,000/mm3 (< 14 x 109/L)

- Absolute neutrophil count (ANC) > 1500 cells/μL (1.5 x 109/L)

- Platelet count ≥ 100,000/μL (≥ 100 x 109/L)

- Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)

- Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT)

- ≤ 1.5 X upper limit of normal (ULN)

- Total bilirubin < 2mg/dL

- Hemoglobin > 11 g/dL Key Exclusion Criteria

- Participation in multiple CC-11050 cohorts or previous exposure to CC-11050

- Presence or history of SLE based on investigators' clinical evaluation where subject
exhibits medically significant (as determined by the Investigator) LE-related
pleuritis, pericarditis, neurologic, renal and/or other major SLE-related organ
system involvement(SLE-related to SLE joint involvement is acceptable).

- Use of topical or any local therapy known to possibly benefit discoid lupus
erythematosus or SCLE sub acute lupus erythematosus within 2 weeks of the Screening
Visit

- Use of concomitant disease modifying anti-rheumatic drugs (DMARDs) with the exception
of anti-malarials within 4 weeks of screening- Use of topical or any local therapy
known to possibly benefit discoid lupus erythematosus or SCLE sub acute lupus
erythematosus within 2 weeks of the Screening Visit

- Use of immunosuppressives (eg, azathioprine, mycophenolate mofetil, methotrexate,
etc.) within 4 weeks of screening